학술논문
POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy
Document Type
Abstract
Author
Source
In Value in Health January 2022 25(1) Supplement:S87-S87
Subject
Language
ISSN
1098-3015